Nightstar Therapeutics (Nightstar Therapeutics) Pre-Tax Income : $-39.30 Mil (TTM As of Mar. 2019)

View and export this data going back to 2017. Start your Free Trial

What is Nightstar Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Nightstar Therapeutics's pretax income for the three months ended in Mar. 2019 was $-16.35 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2019 was $-39.30 Mil. Nightstar Therapeutics's pretax margin was %.

Nightstar Therapeutics Pre-Tax Income Historical Data

The historical data trend for Nightstar Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nightstar Therapeutics Pre-Tax Income Chart

Nightstar Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Pre-Tax Income

-13.65

-12.20

-29.65

-37.30

Nightstar Therapeutics Quarterly Data
	Dec15	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19
Pre-Tax Income	Get a 7-Day Free Trial						-14.36	-8.43	-5.94	-8.58	-16.35

Competitive Comparison of Nightstar Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Nightstar Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nightstar Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nightstar Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Nightstar Therapeutics's Pre-Tax Income falls into.

Nightstar Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Nightstar Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2018 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-44.157	+	3.993	+	0	+	2.862	+	-7.105427357601E-15
	=	-37.30

Nightstar Therapeutics's Pretax Income for the quarter that ended in Mar. 2019 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-18.561	+	1.101	+	0	+	1.107	+	0
	=	-16.35

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.30 Mil.

Nightstar Therapeutics (NAS:NITE) Pre-Tax Income Explanation

Nightstar Therapeutics's Pretax Margin for the quarter that ended in Mar. 2019 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-16.353	/	0
	=	%

Nightstar Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Nightstar Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Nightstar Therapeutics (Nightstar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nightstar Therapeutics PLC (NAS:NITE) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 Euston Road, London, GBR, NW1 2BE

Website

http://www.nightstartx.com

Nightstar Therapeutics Ltd is a clinical-stage gene therapy company. It is focused on developing and commercializing a pipeline of novel and potentially curative, one-time retinal gene therapies for patients suffering from rare inherited retinal diseases. The company's retinal gene therapy product candidate, NSR-REP1, is being developed for the treatment of choroideremia, a rare, degenerative, X-linked genetic retinal disorder primarily affecting males that is caused by a mutation in the CHM gene.

Executives

Nea 15 Gp, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
David Charles Lubner	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Gregory Scott Robinson	officer: Chief Scientific Officer	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
James G Mcarthur	director	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Senthil Vel Sundaram	officer: Chief Financial Officer	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Tuyen Ong	officer: Chief Development Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Paula K Cobb	director	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott M Whitcup	director	2525 DUPONT DRIVE, IRVINE CA 92612
Scott D Sandell	10 percent owner
Nea Partners 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett	10 percent owner